GenFleet Therapeutics and Innovent jointly announced that they have entered into an exclusive license agreement for the development and commercialization of GenFleet's lead KRAS G12C candidate, GFH925 in China with additional option-in rights for global development and commercialization.
GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology worldwide, today announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GFH925 in a multi-center phase I / II clinical trial treating advanced solid tumors among patients with KRAS G12C gene mutation.
The agreement outlines a constructive framework where GenFleet will synergize its own R&D systems with Insilco’s end-to-end AI-powered drug discovery platform and Biortus’ structural biology platform, with a view to jointly addressing significant unmet medical needs and tackling novel & difficult targets in cancer therapeutics.
May 10，2021 (Tianjin, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced that the first patient has been dosed in its first-in-human trial of GFH009.
April 27, 2021 (Melbourne, Australia) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced its first-in-human phase I trial of GFH312 has achieved dosing of subjects in the first cohort.
January 27, 2021 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology
December 21, 2020 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies in oncology and immunology worldwide
November 2, 2020 (Shanghai, China) - GenFleet Therapeutics, a clinical-stage biotechnology company focusing first-in-class therapies in oncology and immunology
